secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001384101-23-000065
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q1 beats: revenue $82.4M (+22%), net loss shrinks 44% to $8.1M
-----------------------------------------------------------------------

- Total revenue $82.4M (+22% YoY); testing revenue $72.4M (+29%); product revenue $3.9M (+31%).
- Net loss improved 44% to $8.1M; diluted EPS -$0.11 from -$0.20.
- Total test volume 28,788 (+24%); ended cash $177.9M near flat.
- Non-GAAP gross margin 68% (vs 65%); operating expenses up 14% to $61.9M.
- Enhanced Afirma test with TERT promoter testing; secured 4 new payer contracts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000065/0001384101-23-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410123000065/vcyt-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001384101-23-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer